Literature DB >> 23958919

Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion.

M Le Garff-Tavernier1, L Herbi2, C de Romeuf3, F Nguyen-Khac4, F Davi4, A Grelier5, M Boudjoghra5, K Maloum5, S Choquet6, R Urbain3, V Vieillard7, H Merle-Béral4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23958919     DOI： 10.1038/leu.2013.240

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.

Authors:  Michaela Patz; Polina Isaeva; Nche Forcob; Bianka Müller; Lukas P Frenzel; Clemens-Martin Wendtner; Christian Klein; Pablo Umana; Michael Hallek; Günter Krause
Journal:  Br J Haematol       Date:  2010-12-13       Impact factor: 6.998

2.  Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.

Authors:  M Le Garff-Tavernier; J Decocq; C de Romeuf; C Parizot; C A Dutertre; E Chapiro; F Davi; P Debré; J F Prost; J L Teillaud; H Merle-Beral; V Vieillard
Journal:  Leukemia       Date:  2010-10-26       Impact factor: 11.528

3.  Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.

Authors:  V Goede; K Fischer; R Busch; U Jaeger; M-S Dilhuydy; N Wickham; S De Guibert; M Ritgen; A W Langerak; G Bieska; A Engelke; K Humphrey; M Wenger; M Hallek
Journal:  Leukemia       Date:  2012-08-31       Impact factor: 11.528

Review 4.  ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.

Authors:  S Pospisilova; D Gonzalez; J Malcikova; M Trbusek; D Rossi; A P Kater; F Cymbalista; B Eichhorst; M Hallek; H Döhner; P Hillmen; M van Oers; J Gribben; P Ghia; E Montserrat; S Stilgenbauer; T Zenz
Journal:  Leukemia       Date:  2012-02-02       Impact factor: 11.528

5.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

6.  Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

Authors:  Thorsten Zenz; Sonja Häbe; Tina Denzel; Julia Mohr; Dirk Winkler; Andreas Bühler; Antonio Sarno; Silja Groner; Daniel Mertens; Raymonde Busch; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2009-07-30       Impact factor: 22.113

7.  Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.

Authors:  Christophe de Romeuf; Charles-Antoine Dutertre; Magali Le Garff-Tavernier; Nathalie Fournier; Christine Gaucher; Arnaud Glacet; Sylvie Jorieux; Nicolas Bihoreau; Christian K Behrens; Roland Béliard; Vincent Vieillard; Bruno Cazin; Dominique Bourel; Jean-François Prost; Jean-Luc Teillaud; Hélène Merle-Béral
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

8.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  Functional assessment of p53 in chronic lymphocytic leukemia.

Authors:  M Le Garff-Tavernier; H Blons; F Nguyen-Khac; M Pannetier; M Brissard; S Gueguen; F Jacob; L Ysebaert; S A Susin; H Merle-Béral
Journal:  Blood Cancer J       Date:  2011-02-25       Impact factor: 11.037

10.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Authors:  D Catovsky; S Richards; E Matutes; D Oscier; Mjs Dyer; R F Bezares; A R Pettitt; T Hamblin; D W Milligan; J A Child; M S Hamilton; C E Dearden; A G Smith; A G Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321
View more
  23 in total

1.  Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Matthew Lunning; Julie Vose; Loretta Nastoupil; Nathan Fowler; Jan A Burger; William G Wierda; Marshall T Schreeder; Tanya Siddiqi; Christopher R Flowers; Jonathon B Cohen; Peter Sportelli; Hari P Miskin; Michael S Weiss; Susan O'Brien
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113

2.  The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.

Authors:  Magali Le Garff-Tavernier; Linda Herbi; Christophe de Romeuf; Nabih Azar; Damien Roos-Weil; Patrick Bonnemye; Rémi Urbain; Véronique Leblond; Hélène Merle-Beral; Vincent Vieillard
Journal:  Haematologica       Date:  2014-12-31       Impact factor: 9.941

Review 3.  Current Treatment of Chronic Lymphocytic Leukemia.

Authors:  Krzysztof Jamroziak; Bartosz Puła; Jan Walewski
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 5.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 6.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 7.  Improving natural killer cell cancer immunotherapy.

Authors:  Melissa M Berrien-Elliott; Rizwan Romee; Todd A Fehniger
Journal:  Curr Opin Organ Transplant       Date:  2015-12       Impact factor: 2.640

8.  The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.

Authors:  Michael Zhong; Anneke van der Walt; Maria Pia Campagna; Jim Stankovich; Helmut Butzkueven; Vilija Jokubaitis
Journal:  Neurotherapeutics       Date:  2020-10-14       Impact factor: 7.620

Review 9.  Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside.

Authors:  Wenli Zhu; Yaling Zhang; Zhen Wang; Ying Fu; Yaping Yan
Journal:  Neurosci Bull       Date:  2020-06-12       Impact factor: 5.203

Review 10.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.